Shareholder Tools

Press Releases

2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 1999
Press Releases
Date Title and Summary View
Oct 2, 2017 - Transformational Transaction Provides Endocyte with the Most Advanced Targeted Radioligand Therapy in Development for Prostate Cancer, Addressing a Greater than $1 Billion Market Opportunity - -  High Response Rates Demonstrated in Late Stage Prostate Cancer Patients in Clinical Data Presented at Recent European Society for Medical Oncolog...
Sep 19, 2017 WEST LAFAYETTE, Ind., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that the company's management team will present at the 2017 Cantor Global Healthcare Conference on Tuesday, Sept. 26, a...
Sep 6, 2017 - Poster further demonstrates the potential of Endocyte's SMDC CAR-T platform to more safely regulate CAR-T therapy for solid tumors - - Unwanted toxicities may be controlled through the administration of approved agents - WEST LAFAYETTE, Ind., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targete...
Sep 5, 2017 WEST LAFAYETTE, Ind., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that a poster will be presented at the European Society for Medical Oncology (ESMO), being held in Madrid, Spain, Sept....
Aug 16, 2017 WEST LAFAYETTE, Ind., Aug. 16, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that four posters will be presented by Endocyte scientists at the 254th American Chemical Society (ACS) National Meeting...
Aug 8, 2017 - Plans to Initiate Clinical Development for CAR T-Cell Program in Osteosarcoma in 2018 - - Nearing Completion of Enrollment of Expansion Phase of EC1169 Trial in Prostate Cancer Patients - - IND filed for Dual-Targeted DNA Crosslinker EC2629 - - Conference Call Today at 4:30 p.m. EDT - WEST LAFAYETTE, Ind., Aug. 08, 2017 (GLOBE NEWSWIRE...
Aug 1, 2017 WEST LAFAYETTE, Ind., Aug. 01, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc., (NASDAQ:ECYT) announced today that the company will host a conference call on Tuesday, Aug. 8th, at 4:30 p.m. EDT to discuss its second quarter financial results and provide an operational update. Investors and the general public are invited to listen to a live webcast o...
Jun 2, 2017 - Company Continuing EC1169 Program in Taxane-Exposed Patients, but Ending Clinical Development of EC1456 and of EC1169 in Taxane-Naïve Patients -  - Refocusing Efforts on Chimeric Antigen Receptor T-cell (CAR T-cell) and Dual-Targeted DNA Crosslinker Drug EC2629 Programs - - Restructuring to Reduce Workforce by Approximately 40%; Will M...
May 26, 2017 WEST LAFAYETTE, Ind., May 26, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced that two posters will be presented on its lead, clinical-stage assets, EC1456 and EC1169, at the 2017 American Society of...
May 10, 2017 WEST LAFAYETTE, Ind., May 10, 2017 (GLOBE NEWSWIRE) -- Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, today announced financial results for the first quarter ending March 31, 2017, and provided a clinical and pipeline update. "We look...
1
NextLast
Add to Briefcase = add release to Briefcase